Issue link: http://osercommunicationsgroup.uberflip.com/i/808989
Chain Drugstore Daily Sunday, April 23, 2017 1 8 ON-THE-GO ACNE STICK FROM OXY OXY ® Acne Medication brings innova- tion to the acne care aisle with a first of its kind, on-the-go benzoyl peroxide acne treatment. OXY, a trusted skin care brand for more than 40 years, is leading innovation with the new OXY On-The-Go Acne Stick, an effective and easy-to-use 5 per- cent benzoyl peroxide acne treatment. Most acne care products are inconven- ient, limiting consumers to a bathroom with a sink and mirror to wash their face and hands to apply treatment, but the portable and mess-free OXY On-The-Go Acne Stick solves that problem. It also promotes out-of-home incremental acne treatments, creating a new usage setting for teenage consumers. "Acne is difficult to deal with at any time, but becomes even more of a con- cern as students go to school," says Erick Estrada, Mentholatum Senior Marketing Director of OTC Brands. "We want to make sure students can have an effective acne treatment to get clear skin, even when they are away from home." The OXY On-The-Go Acne Stick is conveniently packaged in a slim, solid and mess-free form, offering consumers a highly portable option to treat their pimples. The OXY On-The-Go Acne Stick began shipping in January 2017. "I'm excited to announce our new OXY On-The-Go Acne Stick, which is an inno- vative, quick and easy way to treat pimples anytime, any- where." Estrada said. "We developed this unique deliv- ery system with patented Microsponge ® technology, delivering clinically proven 5 percent benzoyl peroxide to kill acne- causing bacteria without over-drying the skin." OXY Acne Medication has a variety of effective and easy to use forms, such as pads, face washes and a spot treatment, and are formu- lated with clinically proven acne- fighting ingredients, like benzoyl peroxide, the No. 1 active ingredi- ent recommended by dermatologists to kill acne bacteria, and salicylic acid, to help clear even the most stubborn acne. OXY products are designed for teens and can be used by various skin types. For more information, visit booth #314 or go to www.oxyskincare.com. OPTIMIZING DIRECT MAIL COMMUNICATIONS WITH PDQ PDQ Communications, a respected leader in the direct mail market, turns its pharmaceutical partners' marketing chal- lenges into opportunities. Through its 100 percent custom mail programs, PDQ reaches all healthcare providers in any practice setting. PDQ will customize mail programs to complement client sales and marketing efforts. "Our customer satisfaction rates are the highest I have seen during my 30 years in this industry," said PDQ Chief Operating Officer, Joanne Andre. Simple to sophisticated, PDQ offers an array of custom mail programs depending on the client's goals, objec- tives and budgets. From small, targeted, local, single-wave mailings to elaborate, national, multi-wave campaigns and everything in between, PDQ takes your direct mail program and makes the process turnkey. Whatever your needs – new product launches, line extensions, managed care announcements, copay assistance pro- grams, new indications or FDA-mandat- ed mailings – PDQ can reach your target audiences in a timely, cost-efficient manner. PDQ works with client sup- plied lists or can provide lists based on your needs, by spe- cialty or sub-specialty, disease state, geo- graphic location or prescribing deciles. Mailings deploy in custom envelopes or vehicles designed to accommodate your mail piece. Additionally, PDQ's in-house production managers are experts in find- ing efficiencies to streamline costs and timelines. When asked what separates them from the competition, PDQ Chief Executive Officer Mary Jane Garvey replied, "We differentiate ourselves with our superior customer service and atten- tion to detail. Every client works with a dedicated PDQ account manager and production man- ager. I've worked for a number of similar companies and am proud to say that PDQ is the best at direct mail for the healthcare industry." Whether your needs demand FDA- mandated mailings in a letter size enve- lope or you are launching a new product, showcasing your message with jazzy art- work in a custom clear envelope, no direct mail job is too big or too small for PDQ. Partner with PDQ Communications and let it turn your mar- keting challenges into opportunities. For more information, call 866.485.4737. AQUINOX ANNOUNCES APPOINTMENT OF DR. KELVIN NEU, DR. RICHARD LEVY TO BOARD OF DIRECTORS Aquinox Pharmaceuticals, Inc., a clini- cal-stage pharmaceutical company dis- covering and developing targeted thera- peutics in disease areas of inflammation and immuno-oncology, announced that representatives from Aquinox's largest shareholder, Baker Brothers Investments, have been appointed to the Aquinox's Board of Directors. Drs. Kelvin M. Neu, M.D. and Richard S. Levy, M.D., joined effective March 23, 2017. Founded in 2000, Baker Brothers Investments man- ages long-term investment funds, focused on publicly traded life sciences companies, for major university endow- ments and foundations. "I would like to welcome Kelvin and Richard to the Board. Baker Brothers Investments has been a strong supporter of the company and we have a shared vision for the potential of Aquinox. We will benefit immensely from an even closer working relationship, their deep insights on successful clinical develop- ment and experience working with many companies to bring novel therapies to market," said David Main, President and Chief Executive Officer of Aquinox. "The strength of our Board reflects our focus on late stage development and preparation for commercialization in support of the company's goal to mean- ingfully improve the quality of patients' lives through innovative medicines." Kelvin M. Neu, M.D., is a Managing Director of Baker Brothers Investments. Dr. Neu holds an M.D. from the Harvard Medical School-MIT Health Sciences and Technology program, and spent three years in the Immunology Ph.D. program at Stanford University as a Howard Hughes Medical Institute Fellow. Richard S. Levy, M.D., is a Senior Advisor at Baker Brothers Investments. Dr. Levy, previously Executive Vice President, Chief Drug Development and Medical Officer at Incyte Corporation, is Board Certified in Internal Medicine and Gastroenterology and received his M.D. from the University of Pennsylvania School of Medicine. About Aquinox Pharmaceuticals, Inc. Aquinox Pharmaceuticals, Inc. is a late clinical-stage pharmaceutical company discovering and developing targeted ther- apeutics in disease areas of inflammation and immuno-oncology. Its primary focus is anti-inflammatory product candidates targeting SH2-containing inositol-5'- phosphatase 1, or SHIP1, which is a key regulator of an important cellular signal- ing pathway in immune cells, known as the PI3K pathway. Aquinox's lead drug candidate, AQX-1125, is a small mole- cule activator of SHIP1 suitable for oral, once daily dosing. In September 2016, it began enrolling patients in a Phase 3 clin- ical trial of AQX-1125 in its lead indica- tion, Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS). Other indications are under consideration for future investi- gation. Aquinox has a broad intellectual property portfolio and pipeline of preclin- ical drug candidates that activate SHIP1. For more information, visit www .aqxpharma.com. NOVELION APPOINTS MARK CORRIGAN TO BOARD OF DIRECTORS Novelion Therapeutics Inc., a biophar- maceutical company dedicated to devel- oping new standards of care for individu- als living with rare diseases, today announced the appointment of Mark Corrigan, M.D. to its board of directors, effective immediately. Corrigan will serve as a member of the compliance committee. Jason Aryeh, Chairman of the board of directors, said, "As a highly successful industry executive and board member, we believe Dr. Corrigan will be a strong contributor to the strategic direction of Novelion, particularly as we seek to max- imize the value of metreleptin by expand- ing the pipeline of indications in devel- opment. In addition, we believe Dr. Corrigan's complementary scientific expertise and strong strategic track record will augment the new board's focus on maximizing shareholder value with proper compliance and strong cor- porate governance." Corrigan was previously president and chief executive officer of Zalicus Inc. Prior to that, he was executive vice president, research & development of Sepracor Inc. (now Sunovion Pharmaceuticals). Prior to joining Sepracor, Corrigan spent 10 years with Pharmacia & Upjohn, Inc., most recently as group vice president of global clinical research and experimental medi- cine. Corrigan currently serves on the board of directors of Cardiome Pharma Corp. (NASDAQ:CRME) and on the supervisory board of Nabriva Therapeutics AG (NAS- DAQ:NBRV). He previously served as a director of CoLucid Pharmaceuticals, Inc., Avanir Pharmaceuticals, Inc., EPIRUS Biopharmaceuticals, Inc. and Cubist Pharmaceuticals, Inc. He was chairman of the board of EPIRUS and served on the audit committee and nominating and gov- ernance committee and chaired the scientif- ic affairs committee of Cubist's board. Corrigan spent five years in academ- ic research at the University of North Carolina Medical School, focusing on psychoneuroendocrinology. He holds a B.A. and an M.D. from the University of Virginia and received specialty training in psychiatry at Maine Medical Center and Cornell University. The company also announced that effective immediately, Sandford ("Sandy") Smith will step down from the Novelion Board of Directors. "We thank Sandy for serving as vice chairman, and for his shared vision towards the creation of Novelion Therapeutics," continued Aryeh.